News

Oblique Therapeutics has yet again received grants from Vinnova.

This year we received funding for 3 different development projects:

  • A new class of selective antagonistic TRPV1 for pain therapyA project we continue to get funded for.
    In collaboration with KI.
  • Engineering of nano-sized membrane vesicles for intracellular delivery of therapeutic antibodiesDesigning a new technology to get antibodies inside the cell
    A project in collaboration with KTH, KI and SLU
  • Improved cancer diagnostic and drug developmentA project in collaboration with RISE among others

6 october

Professor Owe Orwar, CEO of Oblique Therapeutics will make the first public disclosure of the company´s transformative platform for for functional antibody discovery and design at the 3rd Drug Discovery Innovation Programme 5-6 Oct 2017 Munich, Germany. Read more: https://worldbi.co.uk/DDIP/

Oblique Therapeutics has recieved

Oblique Therapeutics has recieved a grant from the Vinnova future biological medicines program to develop functional antibodies against TRPV1 and TRPV2 for inflammatory/idiopathic pain and metastatic cancer, respectively.

Oblique Therapeutics has entered into

Oblique Therapeutics has entered into a discovery agreement with a global leader in diabetes medicines and care regarding the development of two functional antibodies against type 2 diabetes targets.